Multiple Choice
A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to:
A) Decreased effectiveness of irinotecan in the treatment of cancer
B) Increased adverse drug reactions, such as neutropenia
C) Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
D) Increased concerns for irinotecan being carcinogenic
Correct Answer:
Verified
Correct Answer:
Verified
Q2: Ultra-rapid metabolizers of drugs may have:<br>A) To
Q3: Genetic polymorphisms account for differences in metabolism,
Q4: Carbamazepine has a Black Box Warning recommending
Q5: Warfarin resistance may be seen in patients
Q6: A provider may consider testing for CYP2D6
Q7: Patients who have a poor metabolism phenotype
Q8: Rifampin is a nonspecific CYP450 inducer that
Q9: Up to 21% of Asians are ultra-rapid
Q10: Inhibition of P-glycoprotein by a drug such
Q11: Pharmacogenetic testing is required by the U.S.